Thyroid cancer, BRAF-mutated

Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.

2 regimens on this page 2 variants on this page

Differentiated thyroid cancer, all lines of therapy

Vemurafenib monotherapy

back to top

Regimen

Study	Evidence
Brose et al. 2016 (NO25530)	Phase II

Note: this study was in patients with papillary thyroid cancer, only.

Targeted therapy

• Vemurafenib (Zelboraf) 960 mg PO twice per day

Continued indefinitely

References

1. NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains verified protocol link to PMC article PubMed

Anaplastic thyroid cancer, all lines of therapy

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose

Study	Years of enrollment	Evidence	Efficacy
Subbiah et al. 2017 (BRF117019)	2014-2016	Phase II, <20 pts in subgroup (RT)	ORR: 63% (95% CI, 35-85)

Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.

Targeted therapy

• Dabrafenib (Tafinlar) 150 mg PO twice per day
• Trametinib (Mekinist) 2 mg PO once per day

Continued indefinitely

References

1. BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed